Company Overview and News

 
Former Federal Reserve Chair Dr. Janet L. Yellen to Keynote Stifel 2018 Cross Sector Insight Conference

2018-04-10 globenewswire
ST. LOUIS, April 10, 2018 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE:SF) today announced that former Federal Reserve Board Chair Dr. Janet L. Yellen will be a featured keynote speaker at the firm’s upcoming Cross Sector Insight Conference. Dr. Yellen will participate in a lunchtime fireside chat to be moderated by Stifel Chairman and Chief Executive Officer Ron Kruszewski on Wednesday, June 13.
Upvote Downvote

 
GE Revamp: CEO John Flannery Could Do More With Fresh Eyes - Bloomberg

2018-04-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Concho Resources' (CXO) CEO Tim Leach on Concho Resources Acquisition of RSP Permian (Transcript)

2018-03-30 seekingalpha
Concho Resources Inc. (NYSE:CXO) Concho Resources Acquisition of RSP Permian March 28, 2018 8:00 AM ET
Upvote Downvote

 
TD Ameritrade (AMTD) Rallies 11.9% QTD: Is More Upside Left?

2018-03-29 zacks
During the last earnings season, performance of the financial stocks was decent. One such investment bank — TD Ameritrade Holding Corporation (AMTD - Free Report) — has rallied 11.9% quarter to date, significantly outperforming the industry’s slight gain of 1.1%. This price performance is backed by the gradually improving operating environment and rate hike scenario, which is beneficial for brokerage business.
Upvote Downvote

 
UniFirst's (UNF) CEO Steve Sintros on Q2 2018 Results - Earnings Call Transcript

2018-03-28 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Second Quarter Earnings Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded, Wednesday, March 28, 2018.
Upvote Downvote

 
E*TRADE (ETFC) Moves Up 12.1% YTD: Is More Upside Left?

2018-03-27 zacks
During the last earnings season, performance of the financial stocks was decent. One such investment bank — E*TRADE Financial Corporation (ETFC - Free Report) — has rallied 12.1% year to date, significantly outperforming the industry’s slight decline. This price performance is backed by the gradually improving operating environment and rate hike scenario, which is beneficial for brokerage business.
Upvote Downvote

 
Paychex's (PAYX) CEO Martin Mucci on Q3 2018 Results - Earnings Call Transcript

2018-03-26 seekingalpha
Welcome and thank you for standing by. At this time, all participants are in a listen-only mode. For the presentation, we’ll conduct a question-and-answer session. [Operator Instructions] Today’s call is being recorded. If you have any objections, you may disconnect from the conference.
Upvote Downvote

 
5 Reasons to Bet on Stifel Financial (SF) Stock Right Now

2018-03-21 zacks
With cost-reduction initiatives and remarkable balance-sheet growth, Stifel Financial Corp. (SF - Free Report) appears to be a solid bet now. In addition, interest rate hikes and improving economy are anticipated to further stabilize the top line. Further, analysts seem to be optimistic about the company’s prospects as the stock is witnessing upward estimate revisions. Over the past 60 days, the Zacks Consensus Estimate for the current year has risen nearly 1% to $5.
Upvote Downvote

 
Morgan Stanley (MS) Unit Completes Buyout of Mesa West

2018-03-20 zacks
Morgan Stanley Investment Management, a unit of Morgan Stanley (MS - Free Report) , has successfully completed the acquisition of Los Angeles, CA-based commercial real estate credit platform, Mesa West Capital, LLC. Mesa West is a leading, originations-focused, commercial real estate credit platform that has originated 250 loans since its inception in 2004, totaling $12 billion in principal balance.
Upvote Downvote

 
Stifel (SF) Closes Acquisition of Ziegler Wealth Management

2018-03-20 zacks
Stifel Financial Corp. (SF - Free Report) recently announced the completion of the acquisition of B.C. Ziegler & Company’s wealth management business, Ziegler Wealth Management. The transaction, with no financial terms disclosed, was announced in October 2017.
Upvote Downvote

 
Stifel Completes Acquisition of Ziegler Wealth Management

2018-03-19 globenewswire
ST. LOUIS, March 19, 2018 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE:SF) today announced that it has completed the acquisition of Ziegler Wealth Management.
Upvote Downvote

1
NTRP / Neurotrope, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-03-08 fintel.io
Neurotrope, Inc. (NASDAQ:NTRP) has 27 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,543,294 shares. Largest shareholders include Neurosciences Research Ventures, Inc., Cannell Peter B & Co Inc, Vanguard Group Inc, Tanaka Capital Management Inc, Oaktop Capital Management II, L.P., Stifel Financial Corp, Iroquois Capital Management, LLC, First Republic Investment Management, Inc.
Upvote Downvote

 
Bill Barrett (BBG) Q4 2017 Results - Earnings Call Transcript

2018-02-28 seekingalpha
Good day, ladies and gentlemen, and welcome to the Bill Barrett Corporation Fourth Quarter and Full Year 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.
Upvote Downvote

 
NIQ / Nuveen Intermediate Duration Quality Municipal Term Fund - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-27 fintel.io
Nuveen Intermediate Duration Quality Municipal Term Fund (NYSE:NIQ) has 36 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,070,670 shares. Largest shareholders include HighTower Advisors, LLC, Rivernorth Capital Management, Llc, Morgan Stanley, Stifel Financial Corp, Wells Fargo & Company/mn, Usca Ria Llc, Guggenheim Capital Llc, Invesco Ltd.
Upvote Downvote

 
FNBG / FNB Bancorp - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-21 fintel.io
FNB Bancorp (NASDAQ:FNBG) has 50 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,666,985 shares. Largest shareholders include Brown Trout Management, LLC, Banc Funds Co Llc, Vanguard Group Inc, BlackRock Inc., State Street Corp, San Francisco Sentry Investment Group (ca), Northern Trust Corp, Stifel Financial Corp, Deutsche Bank Ag\, and Renaissance Technologies LLC.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...